scholarly journals Analgesic Effects of Nonsteroidal Anti-inflammatory Drugs in Cancer Pain Due to Somatic or Visceral Mechanisms

1999 ◽  
Vol 17 (5) ◽  
pp. 351-356 ◽  
Author(s):  
Sebastiano Mercadante ◽  
Alessandra Casuccio ◽  
Antonio Agnello ◽  
Salvatore Pumo ◽  
Jafar Kargar ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Analgesic Effects ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

scholarly journals Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults

2017 ◽  
Author(s):  
Sheena Derry ◽  
Philip J Wiffen ◽  
R Andrew Moore ◽  
Ewan D McNicol ◽  
Rae F Bell ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

scholarly journals Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents

2017 ◽  
Author(s):  
Christopher Eccleston ◽  
Tess E Cooper ◽  
Emma Fisher ◽  
Brian Anderson ◽  
Nick MR Wilkinson
Keyword(s):  
Cancer Pain ◽  
Children And Adolescents ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Potential Effects of Nonsteroidal Anti-Inflammatory Drugs in the Prevention and Treatment of Type 2 Diabetes Mellitus

2016 ◽  
Vol 30 (5) ◽  
pp. 549-556 ◽  
Author(s):  
Pamela Natalia Bellucci ◽  
María Florencia González Bagnes ◽  
Guillermo Di Girolamo ◽  
Claudio Daniel González
Keyword(s):  
Diabetes Mellitus ◽  
Glucose Production ◽  
Endogenous Glucose Production ◽  
Metabolic Effects ◽  
Analgesic Effects ◽  
Peripheral Insulin Resistance ◽  
Patients With Diabetes ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Nonsteroidal anti-inflammatory drugs (NSAIDs) are a group of heterogeneous drugs largely known for their anti-inflammatory, antipyretic, and analgesic effects, which are met by means of the inhibition of the cyclooxygenase (COX) enzymes. Even when their use in patients with diabetes mellitus is limited due to relevant adverse events, some pharmacological and metabolic effects of NSAIDs have been further studied to be potentially beneficial in the prevention and/or treatment of diabetic subjects. Effects on endogenous glucose production, peripheral insulin resistance, pancreatic islet, and systemic inflammation and the insulin clearance have been reported. In this article, we overview the scientific literature of the last 5 years regarding the potential effects of NSAID treatment on diabetes prevention/treatment. The selected papers showed information in both humans and animal models. Furthermore, we included papers that suggest new areas for further investigation, and we discussed our own suggestions on this matter.

scholarly journals The analgesic effects of non-steroidal anti-inflammatory drugs on acetylcholine-induced writhing in mice.

1984 ◽  
Vol 84 (6) ◽  
pp. 543-551 ◽  
Author(s):  
Fusao AMANUMA ◽  
Chieko WAKAUMI ◽  
Makoto TANAKA ◽  
Makoto MURAMATSU ◽  
Hironaka AIHARA
Keyword(s):  
Analgesic Effects ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

scholarly journals Metamizole/dipyrone for the relief of cancer pain: A systematic review and evidence-based recommendations for clinical practice

2016 ◽  
Vol 31 (1) ◽  
pp. 26-34 ◽  
Author(s):  
Jan Gaertner ◽  
Ulrike M Stamer ◽  
Constanze Remi ◽  
Raymond Voltz ◽  
Claudia Bausewein ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cancer Pain ◽  
Pain Intensity ◽  
Oral Morphine ◽  
Cochrane Library ◽  
Evidence Based ◽  
Low Doses ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Background: Dipyrone (metamizole) is one of the most widely used non-opioid analgesics for the treatment of cancer pain. Aim: Because evidence-based recommendations are not yet available, a systematic review was conducted for the German Guideline Program in Oncology to provide recommendations for the use of dipyrone in cancer pain. Design: First, a systematic review for clinical trials assessing dipyrone in adult patients with cancer pain was conducted. Endpoints were pain intensity, opioid-sparing effects, safety, and quality of life. Data sources: The search was performed in MedLine, Embase (via Ovid), and the Cochrane Library (1948–2013) and additional hand search was conducted. Finally, recommendations were developed and agreed in a formal structured consensus process by 53 representatives of scientific medical societies and 49 experts. Results: Of 177 retrieved studies, 4 could be included (3 randomized controlled trials and 1 cohort study, n = 252 patients): dipyrone significantly decreased pain intensity compared to placebo, even if low doses (1.5–2 g/day) were used. Higher doses (3 × 2 g/day) were more effective than low doses (3 × 1 g/day), but equally effective as 60 mg oral morphine/day. Pain reduction of dipyrone and non-steroidal anti-inflammatory drugs did not differ significantly. Compared to placebo, non-steroidal anti-inflammatory drugs, and morphine, the incidence of adverse effects was not increased. Conclusion: Dipyrone can be recommended for the treatment of cancer pain as an alternative to other non-opioids either alone or in combination with opioids. It can be preferred over non-steroidal anti-inflammatory drugs due to the presumably favorable side effect profile in long-term use, but comparative studies are not available for long-term use.

scholarly journals The safety of nonsteroidal anti-inflammatory drugs in population-based studies: the benefits of aceclofenac

2020 ◽  
Vol 14 (4) ◽  
pp. 138-143
Author(s):  
E. Yu. Pogozheva ◽  
A. E. Karateev ◽  
V. N. Amirdzhanova
Keyword(s):  
Randomized Clinical Trials ◽  
Population Based ◽  
Minimal Risk ◽  
The European Union ◽  
Analgesic Effects ◽  
Quality Of Medical Care ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Effective Pain Relief ◽  
Meta Analyses

Effective pain relief in rheumatology practice is one of the most important criteria for the quality of medical care. Therefore, drugs with analgesic effects, primarily nonsteroidal anti-inflammatory drugs (NSAIDs), are among the most commonly used ones in the combination therapy of rheumatic diseases. All NSAIDs are capable of causing to one degree or another extent unwanted reactions that occur in the gastrointestinal tract (GIT), cardiovascular system (CVS), liver, kidneys, and allergic reactions. Considering the widespread use of NSAIDs, the problem of preventing these complications becomes not only medical, but also social. In 2008, the European Union launched the international project SOS (Safety Of non-Steroidal anti-inflammatory drugs) to study the safety of NSAIDs. The results of this project have shown that aceclofenac is one of the most successful drugs in combining the safety for GIT and CVS. Compared with other NSAIDs, this drug has a minimal risk for GI bleeding (relative risk (RR) 1.43; 95% confidence interval (CI), 0.65–3.15); it does not increase the risk of hospitalization for heart failure (RR, 1.03; 95% CI, 0.91–1.15) or the risk of developing myocardial infarction (RR 1.04; 95% CI, 0.90–1.19) either. The risk of ischemic stroke during aceclofenac therapy was slightly increased (RR, 1.17); but statistically insignificant (95% CI, 0.98–1.39). A large number of randomized clinical trials, meta-analyses, and observational programs have demonstrated that aceclofenac has pronounced analgesic and anti-inflammatory effects that are comparable to those of other NSAIDs and can be used in diseases accompanied by musculoskeletal pain, including that in older patients.

scholarly journals Alflutop - in modern symptom - modifying osteoarthritis therapy

2019 ◽  
Vol 91 (5) ◽  
pp. 134-140 ◽  
Author(s):  
V N Drozdov ◽  
E V Shikh ◽  
S Y Serebrova ◽  
A G Abrosimov ◽  
A K Starodubtsev
Keyword(s):  
Adverse Drug Events ◽  
Treatment Strategies ◽  
Analgesic Effects ◽  
Human Hyaline Cartilage ◽  
High Incidence ◽  
Modifying Effect ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Complex Drug

One of the serious problems during the treatment of osteoarthritis (OA) is the developing of adverse drug events during therapy. Nonsteroidal anti - inflammatory drugs (NSAIDs) are the first drugs with the high incidence and severity of adverse events. This article describes OA treatment strategies approaches for OA are presented using the complex drug Alflutop, which has a composition similar to the human hyaline cartilage. The drug has anti - inflammatory and analgesic effects, normalizes the function of the affected joints, improves the quality of patients’ life, also has a structure - modifying effect. Such therapy is safe, well tolerable for patients, and can be used used as a starting complex OA treatment.

Designing a clinical trial of non-steroidal anti-inflammatory drugs for cancer pain: a survey of UK palliative care physicians

2020 ◽  
pp. bmjspcare-2020-002792
Author(s):  
Andrew J Page ◽  
Matthew R Mulvey ◽  
Michael I Bennett
Keyword(s):  
Palliative Care ◽  
Cancer Pain ◽  
Palliative Medicine ◽  
Bone Pain ◽  
Controlled Trial ◽  
Perceived Efficacy ◽  
Inflammatory Drugs ◽  
Cox 2 ◽  
Anti Inflammatory ◽  
Cox 2 Inhibitors

ObjectivesInsufficient quality evidence exists to support or refute the use of non-steroidal anti-inflammatory drugs (NSAIDs) in the management of cancer pain. We aimed to determine the most clinically pragmatic design of a future randominsed controlled trial (RCT), based on how NSAIDs are currently used and perceived efficacy.MethodsAn online survey was distributed to members of the Association for Palliative Medicine of Great Britain and Ireland examining NSAID use, indications and perceived efficacy, as well as duration of respondents’ experience in palliative medicine.Results23% of 968 members responded. A placebo-controlled trial of NSAIDs as a strong opioid adjunct in cancer-related bone pain was considered the most clinically pragmatic design. Concerning current practice, oral administration was the preferential route (79.4%), dosed regularly (79.5%). Selective cyclooxygenase-2 (COX-2) inhibitors and non-selective COX-2 inhibitors were considered similarly effective by 45% in cancer pain; ibuprofen being the first line oral NSAID of choice (42.6%). Treatment efficacy is generally determined within 1 week (94.3%). On a Likert scale, most physicians consider NSAIDs improve cancer pain either ‘sometimes’ (57.7%) or ‘often’ (40%). Years of specialist palliative care experience did not affect perception of efficacy (p=0.353).ConclusionsA randomised controlled trial of NSAIDs as opioid adjuncts for cancer-related bone pain would be the most pragmatic design supported by palliative care clinicians to benefit clinical practice.

Sign in / Sign up

Export Citation Format

Share Document